

Amyotrophic Lateral Sclerosis Market Insight, Epidemiology and Market Forecast -2030

<https://marketpublishers.com/r/A021C3B2A874EN.html>

Date: December 2020

Pages: 309

Price: US\$ 6,950.00 (Single User License)

ID: A021C3B2A874EN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's 'Amyotrophic Lateral Sclerosis (ALS) - Market Insights, Epidemiology and Market Forecast– 2030' report delivers an in-depth understanding of the ALS , historical and forecasted epidemiology as well as the ALS market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The ALS market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM ALS market size from 2017 to 2030. The report also covers current ALS treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

The United States

EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Japan

Study Period: 2017–2030

Amyotrophic Lateral Sclerosis (ALS) Disease Understanding and Treatment Algorithm

Amyotrophic Lateral Sclerosis (ALS) Overview

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a group of rare neurological diseases that mainly involve the nerve cells (neurons) responsible for controlling voluntary muscle movement. The disease is progressive, meaning the symptoms get worse over time. In ALS, both the upper motor neurons and the lower motor neurons degenerate or die and stop sending messages to the muscles. Unable to function, the muscles gradually weaken, start to twitch (called fasciculations), and waste away (atrophy). Eventually, the brain loses its ability to initiate and control voluntary movements. The cause of ALS is not known, and it is not yet known why ALS strikes some people and not others. However, evidence from scientific studies suggests that both genetics and environment play a role in the development of ALS.

In ALS, both the upper motor neurons and the lower motor neurons degenerate or die and stop sending messages to the muscles. Unable to function, the muscles gradually weaken, start to twitch (called fasciculations), and waste away (atrophy). Eventually, the brain loses its ability to initiate and control voluntary movements. The cause of ALS is not known, and it is not yet known why ALS strikes some people and not others. However, evidence from scientific studies suggests that both genetics and environment play a role in the development of ALS.

ALS can affect any of the body's muscles, which is why it affects each person differently. In addition, ALS progresses at different rates in different people. For some, it advances quickly, and in others, the disease shows a much slower pace. Common symptoms include painless, progressive muscle weakness. The first thing a person might notice is tripping more often, or dropping things because of the weakness. Slurred speech, difficulty swallowing, and trouble breathing can occur.

ALS can be either sporadic or genetic. The sporadic type is the most common. It accounts for 90–95% of all cases of ALS. The sporadic type can affect anyone. The genetic or familial type is rarer and accounts for 5–10% of cases of ALS. The terms familial and genetic mean that this type of ALS is inherited. In families who have genetic ALS, there is an up to 50% chance that each child will inherit the gene and develop the disease.

Amyotrophic Lateral Sclerosis (ALS) Diagnosis

No one test can provide a definitive diagnosis of ALS. ALS is primarily diagnosed based on a detailed history of the symptoms and signs observed by a physician during

physical examination along with a series of tests to rule out other mimicking diseases. However, the presence of upper and lower motor neuron symptoms strongly suggests the presence of the disease. Tests that may help diagnose ALS are electromyography (EMG), nerve conduction study (NCS), magnetic resonance imaging (MRI). Further tests to rule out other conditions may include blood and urine tests and a muscle biopsy. Medical problems that can produce similar symptoms to ALS, such as HIV, Lyme disease, multiple sclerosis (MS), the poliovirus, and the West Nile virus (WNV), should be considered when making a diagnosis.

Amyotrophic Lateral Sclerosis (ALS) Treatment

There is no cure for ALS, so treatment aims to alleviate symptoms, prevent unnecessary complications, and slow the rate of disease progression. Medical interventions and technology have vastly improved the quality of life for people with ALS by assisting with breathing, nutrition, mobility, and communication. Proper management of symptoms and proactive use of medical interventions and equipment can make a positive difference in day-to-day living and potentially may lengthen life.

The cornerstone of disease management for ALS patients remains multidisciplinary care, which has a positive effect on patient satisfaction and outcome. Several discomforting symptoms of ALS can be managed by symptomatic treatment options, including pharmacological and non-pharmacological interventions. For instance, spasticity can be treated with baclofen, tizanidine, cannabinoids, and muscle stretching, and sialorrhea can be treated with anticholinergic medications (amitriptyline, glycopyrronium bromide and oxybutynin) and botulin toxin injections into the salivatory glands. Muscle cramps may respond to magnesium supplements, quinine sulfate, gabapentin, or carbamazepine. Selective serotonin reuptake inhibitors, amitriptyline, benzodiazepines, and dextromethorphan hydrobromide/quinidine sulfate, can be used in the case of emotional lability. Dietary changes can improve nutrition, and a gastrostomy tube is an option if the caloric intake is insufficient or when swallowing becomes hazardous. Speech therapy is frequently necessary, and assisted communication (customized software) can also be used. Non-invasive ventilation is the preferred life-prolonging treatment for respiratory insufficiency.

Amyotrophic Lateral Sclerosis (ALS) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Population of Amyotrophic Lateral Sclerosis (ALS), Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis (ALS), Gender-

specific Distribution of Amyotrophic Lateral Sclerosis (ALS), Type-specific Distribution of Amyotrophic Lateral Sclerosis (ALS), Mutation-specific Distribution of Amyotrophic Lateral Sclerosis (ALS), Site of Onset of Amyotrophic Lateral Sclerosis (ALS) and Age-specific Distribution of ALS in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Key Findings

This section provides glimpse of the ALS epidemiology in the 7MM.

The prevalent population of ALS in the seven major markets was found to be 70,456 in 2017.

The diagnosed prevalent cases of ALS, in the United States, were found to be 45,796 in 2017 and 48,112 in 2020.

In the United States, the sporadic and familial ALS cases were 16,015 and 1,779, respectively, in 2017.

In the United States, the number of males and females with ALS were 11,482 and 7,341, respectively, in 2020.

ALS can be divided into C9ORF72, SOD1, others mutations (TARDBP, FUS, OPTN, ANG, etc.), and non-mutated/unidentified mutation based on the types of mutations causing the condition. In the United States, the number of cases of C9ORF72, SOD1, others mutations (TARDBP, FUS, OPTN, ANG, etc.), and non-mutated/unidentified mutation was 5,783, 2,847, 1,424 and 7,741, respectively, in 2017.

In the United States, the most diagnosed site of onset of ALS was limb with 8,897 cases, followed by bulbar and cervical with 4,449 and 2,491 cases, and other uncertain regions accounted for 1,957 cases in 2017.

Age-specific data of ALS suggests that it is more prevalent among the 60–69 age group. In the United States, the maximum number of cases of ALS was observed in the age group of 60–69 with 5,623 cases in 2017, while the lowest number of cases were found in the age group

Contents

1 KEY INSIGHTS

2 EXECUTIVE SUMMARY

3 AMYOTROPHIC LATERAL SCLEROSIS (ALS) MARKET OVERVIEW AT A GLANCE

3.1 Market Share (%) Distribution of Amyotrophic Lateral Sclerosis (ALS) in 2017

3.2 Market Share (%) Distribution of Amyotrophic Lateral Sclerosis (ALS) in 2030

4 DISEASE BACKGROUND AND OVERVIEW: AMYOTROPHIC LATERAL SCLEROSIS (ALS)

4.1 Introduction

4.2 Types of ALS

4.2.1 Sporadic ALS

4.2.2 Genetic or Familial ALS

4.3 Causes

4.3.1 Genetics

4.3.2 Environmental factors

4.4 Risk factors

4.5 Symptoms

4.6 Clinical Features

4.6.1 Clinical presentation

4.6.2 Amyotrophic lateral sclerosis phenotypes

4.6.3 Subtypes of ALS based on relative UMN versus LMN involvement

4.6.4 Subtypes of motor neuron disease based on the regional distribution of involvement

4.6.5 Subtypes of ALS based on additional frontotemporal involvement

4.7 Pathogenesis

4.7.1 Failure of proteostasis

4.7.2 Disturbed RNA metabolism

4.7.3 Cytoskeletal disturbances and axonal transport defects

4.8 Biomarker

4.9 Prediction of prognosis

4.10 Differential Diagnosis

4.11 Diagnosis

4.11.1 Criteria and requirements for diagnosis

5 EUROPEAN FEDERATION OF NEUROLOGICAL SOCIETIES (EFNS) GUIDELINES ON THE CLINICAL MANAGEMENT OF AMYOTROPHIC LATERAL SCLEROSIS (MALS) (2012)

6 RECOGNIZED ESTABLISHMENTS

7 TREATMENT AND MANAGEMENT OF ALS

7.1 Multidisciplinary Care

7.2 Neuroprotective Treatments

7.2.1 Riluzole

7.2.2 Edaravone

7.2.3 Nuedexta

7.3 Symptomatic Treatments

7.4 Adaptive and Assistive Equipment

7.5 Nutrition

7.6 Respiratory Management

7.7 Secretion Management

7.8 Palliative and End-of-Life Care

8 EUROPEAN FEDERATION OF NEUROLOGICAL SOCIETIES (EFNS) GUIDELINES ON THE CLINICAL MANAGEMENT OF AMYOTROPHIC LATERAL SCLEROSIS (MALS) (2012)

9 AMERICAN ASSOCIATION OF NEUROLOGY (AAN) GUIDELINES FOR CARE AND MANAGEMENT OF PATIENTS WITH ALS (2009)

10 MANAGEMENT ALGORITHM FOR RESPIRATORY DYSFUNCTION IN ALS

11 MANAGEMENT GUIDELINES FOR ALS IN JAPAN, THE UNITED STATES, AND EUROPE.

12 EPIDEMIOLOGY AND PATIENT POPULATION

12.1 Key Findings

12.2 7MM Prevalent Population of Amyotrophic Lateral Sclerosis

12.3 7MM Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis

13 COUNTRY WISE-EPIDEMIOLOGY OF AMYOTROPHIC LATERAL SCLEROSIS

13.1 United States

13.1.1 Assumptions and Rationale

13.1.2 Prevalence of Amyotrophic Lateral Sclerosis in the United States

13.1.3 Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in the United States

13.1.4 Gender-specific Distribution of Amyotrophic Lateral Sclerosis in the United States

13.1.5 Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in the United States

13.1.6 Type-specific Distribution of Amyotrophic Lateral Sclerosis in the United States

13.1.7 Site of onset of Amyotrophic Lateral Sclerosis in the United States

13.1.8 Age-specific Distribution of Amyotrophic Lateral Sclerosis in the United States

13.2 EU5 Countries

13.3 Germany

13.3.1 Assumptions and Rationale

13.3.2 Prevalence of Amyotrophic Lateral Sclerosis in Germany

13.3.3 Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in Germany

13.3.4 Gender-specific Distribution of Amyotrophic Lateral Sclerosis in Germany

13.3.5 Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in Germany

13.3.6 Type-specific Distribution of Amyotrophic Lateral Sclerosis in Germany

13.3.7 Site of onset of Amyotrophic Lateral Sclerosis in Germany

13.3.8 Age-specific Distribution of Amyotrophic Lateral Sclerosis in Germany

13.4 France

13.4.1 Assumptions and Rationale

13.4.2 Prevalence of Amyotrophic Lateral Sclerosis in France

13.4.3 Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in France

13.4.4 Gender-specific Distribution of Amyotrophic Lateral Sclerosis in France

13.4.5 Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in France

13.4.6 Type-specific Distribution of Amyotrophic Lateral Sclerosis in France

13.4.7 Site of onset of Amyotrophic Lateral Sclerosis in France

13.4.8 Age-specific Distribution of Amyotrophic Lateral Sclerosis in France

13.5 Italy

13.5.1 Assumptions and Rationale

13.5.2 Prevalence of Amyotrophic Lateral Sclerosis in Italy

13.5.3 Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in Italy

13.5.4 Gender-specific Distribution of Amyotrophic Lateral Sclerosis in Italy

13.5.5 Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in Italy

- 13.5.6 Type-specific Distribution of Amyotrophic Lateral Sclerosis in Italy
- 13.5.7 Site of onset of Amyotrophic Lateral Sclerosis in Italy
- 13.5.8 Age-specific Distribution of Amyotrophic Lateral Sclerosis in Italy
- 13.6 Spain
 - 13.6.1 Assumptions and Rationale
 - 13.6.2 Prevalence of Amyotrophic Lateral Sclerosis in Spain
 - 13.6.3 Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in Spain
 - 13.6.4 Gender-specific Distribution of Amyotrophic Lateral Sclerosis in Spain
 - 13.6.5 Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in Spain
 - 13.6.6 Type-specific Distribution of Amyotrophic Lateral Sclerosis in Spain
 - 13.6.7 Site of onset of Amyotrophic Lateral Sclerosis in Spain
 - 13.6.8 Age-specific Distribution of Amyotrophic Lateral Sclerosis in Spain
- 13.7 United Kingdom
 - 13.7.1 Assumptions and Rationale
 - 13.7.2 Prevalence of Amyotrophic Lateral Sclerosis in the United Kingdom
 - 13.7.3 Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in the United Kingdom
 - 13.7.4 Gender-specific Distribution of Amyotrophic Lateral Sclerosis in the United Kingdom
 - 13.7.5 Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in the United Kingdom
 - 13.7.6 Type-specific Distribution of Amyotrophic Lateral Sclerosis in the United Kingdom
 - 13.7.7 Site of onset of Amyotrophic Lateral Sclerosis in the United Kingdom
 - 13.7.8 Age-specific Distribution of Amyotrophic Lateral Sclerosis in the United Kingdom
- 13.8 Japan
 - 13.8.1 Assumptions and Rationale
 - 13.8.2 Prevalence of Amyotrophic Lateral Sclerosis in Japan
 - 13.8.3 Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in Japan
 - 13.8.4 Gender-specific Distribution of Amyotrophic Lateral Sclerosis in Japan
 - 13.8.5 Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in Japan
 - 13.8.6 Type-specific Distribution of Amyotrophic Lateral Sclerosis in Japan
 - 13.8.7 Site of onset of Amyotrophic Lateral Sclerosis in Japan
 - 13.8.8 Age-specific Distribution of Amyotrophic Lateral Sclerosis in Japan

14 UNMET NEEDS

15 MARKETING DRUGS

15.1 Key Competitor

15.1 Radicava (edaravone injection): Mitsubishi Tanabe Pharma Corporation

15.1.1 Drug Description

15.1.2 Regulatory Milestones

15.1.3 Other Developmental Activities

15.1.4 Safety and Efficacy

15.1.5 Product Profile

15.2 Rilutek (Riluzole): Sanofi/Covis

15.2.1 Drug Description

15.2.2 Regulatory Milestones

15.2.3 Other Developmental activities

15.2.4 Safety and Efficacy

15.2.5 Product Profile

15.3 Exservan (Riluzole oral film): Aquestive Therapeutics

15.3.1 Drug Description

15.3.2 Regulatory Milestones

15.3.3 Other Developmental Activities

15.3.4 Safety and Efficacy

15.1.5 Product Profile

15.4 Nuedexta (dextromethorphan hydrobromide/quinidine sulfate): Avanir Pharmaceuticals

(a subsidiary of Otsuka America)

15.4.1 Drug Description

15.4.2 Regulatory Milestones

15.4.3 Other Developmental Activities

15.4.4 Safety and Efficacy

15.1.1 Product Profile

15.5 Tiglutik (riluzole): ITF Pharma (a US subsidiary Italfarmaco S.p.A.)

15.5.1 Drug Description

15.5.2 Regulatory Milestones

15.5.3 Other Developmental Activities

15.5.4 Safety and Efficacy

15.5.5 Product Profile

16 EMERGING DRUGS

16.1 Key Competitor

16.2 Arimoclomol: Orphazyme

16.2.1 Drug Description

- 16.2.2 Other Development Activities
- 16.2.3 Clinical Development
- 16.2.4 Safety and Efficacy
- 16.2.5 Product Profile
- 16.3 Tofersen (BIIB067): Biogen
 - 16.3.1 Drug Description
 - 16.3.2 Other Development Activities
 - 16.3.3 Clinical Development
 - 16.3.4 Safety and Efficacy
 - 16.3.5 Product Profile
- 16.4 Levosimendan: Orion Pharma
 - 16.4.1 Drug Description
 - 16.4.2 Other Development Activities
 - 16.4.3 Clinical Development
 - 16.4.4 Safety and Efficacy
 - 16.4.5 Product Profile
- 16.5 NurOwn (MSC-NTF cells): Brainstorm Cell Therapeutics
 - 16.5.1 Drug Description
 - 16.5.2 Other Development Activities
 - 16.5.3 Clinical Development
 - 16.5.4 Safety and Efficacy
 - 16.5.5 Product Profile
- 16.6 Masitinib: AB Science
 - 16.6.1 Product Description
 - 16.6.2 Other Developmental Activities
 - 16.6.3 Clinical Development
 - 16.6.4 Safety and Efficacy
 - 16.6.5 Product Profile
- 16.7 Ultomiris (ravulizumab): Alexion Pharmaceuticals
 - 16.7.1 Product Description
 - 16.7.2 Other Developmental Activities
 - 16.7.3 Clinical Development
 - 16.7.4 Product Profile
- 16.8 Tirasemtiv: Cytokinetics
 - 16.8.1 Drug Description
 - 16.8.2 Other Development Activities
 - 16.8.3 Clinical Development
 - 16.8.4 Safety and Efficacy
 - 16.8.5 Product Profile

16.9 Verdiperstat: Biohaven Pharmaceuticals**16.9.1 Drug Description****16.9.2 Other Development Activities****16.9.3 Clinical Development****16.9.4 Product Profile****16.10 Ibudilast (MN-166): MediciNova****16.10.1 Product Description****16.10.2 Other Developmental Activities****16.10.3 Clinical Development****16.10.4 Safety and Efficacy****16.10.5 Product Profile****16.11 AMX0035: Amylyx Pharmaceuticals****16.11.1 Product Description****16.11.2 Other Developmental Activities****16.11.3 Clinical Development****16.11.4 Safety and Efficacy****16.11.5 Product Profile****16.12 Zilucoplan: UCB Pharma****16.12.1 Product Description****16.12.2 Other Developmental Activities****16.12.3 Clinical Development****16.12.4 Product Profile****16.13 Gold Nanocrystals/CNM-Au8: Clene Nanomedicine****16.13.1 Drug Description****16.13.2 Other Development Activities****16.13.3 Clinical Development****16.13.4 Product Profile****16.14 Cromolyn sodium (ALZT-OP1a): AZTherapies****16.14.1 Product Description****16.14.2 Other Developmental Activities****16.14.3 Clinical Development****16.14.4 Product Profile****16.15 Reldesemtiv: Cytokinetics/Astellas Pharma****16.15.1 Drug Description****16.15.2 Other Development Activities****16.15.3 Clinical Development****16.15.4 Safety and Efficacy****16.15.5 Product Profile****16.16 RNS60: Revalesio Corporation**

- 16.16.1 Drug Description
- 16.16.2 Other Development Activities
- 16.16.3 Clinical Development
- 16.16.4 Safety and Efficacy
- 16.16.5 Product Profile
- 16.17 ANX005: Annexon
 - 16.17.1 Drug Description
 - 16.17.2 Other Development Activities
 - 16.17.3 Clinical Development
 - 16.17.4 Product Profile
- 16.18 PU-AD: Samus Therapeutics
 - 16.18.1 Drug Description
 - 16.18.2 Clinical Development
 - 16.18.3 Product Profile
- 16.19 Ezogabine/Potiga/Retigabine: GlaxoSmithKline
 - 16.19.1 Drug Description
 - 16.19.2 Other Developmental Activities
 - 16.19.3 Clinical Development
 - 16.19.4 Safety and Efficacy
 - 16.19.5 Product Profile
- 16.2 Pegcetacoplan (APL-2): Apellis Pharmaceuticals
 - 16.20.1 Drug Description
 - 16.20.2 Clinical Development
 - 16.20.3 Product Profile
- 16.21 AT-1501: Novus Therapeutics
 - 16.21.1 Product Description
 - 16.21.2 Other Developmental Activities
 - 16.21.3 Clinical Development
 - 16.21.4 Safety and Efficacy
 - 16.21.5 Product Profile
- 16.22 Ranolazine: Gilead Sciences
 - 16.22.1 Product Description
 - 16.22.2 Clinical Development
 - 16.22.3 Safety and Efficacy
 - 16.22.4 Product Profile
- 16.23 ILB: TikoMed AB/Neuregenix
 - 16.23.1 Product Description
 - 16.23.2 Other Developmental Activities
 - 16.23.3 Clinical Development

- 16.23.4 Product Profile
- 16.24 BLZ945: Novartis Pharmaceuticals
 - 16.24.1 Drug Description
 - 16.24.2 Clinical Development
 - 16.24.3 Product Profile
- 16.25 EPI-589: PTC Therapeutics/ Dainippon Sumitomo Pharma
 - 16.25.1 Drug Description
 - 16.25.2 Other Development Activities
 - 16.25.3 Clinical Development
 - 16.25.4 Safety and Efficacy
 - 16.25.5 Product Profile
- 16.26 IONIS-C9Rx/BIIB078: Ionis Pharmaceuticals/Biogen
 - 16.26.1 Drug Description
 - 16.26.2 Other Development Activities
 - 16.26.3 Clinical Development
 - 16.26.4 Product Profile
- 16.27 ION541/BIIB105: Ionis Pharmaceuticals/Biogen
 - 16.27.1 Drug Description
 - 16.27.2 Other Development Activities
 - 16.27.3 Clinical Development
 - 16.27.4 Product Profile

17 MARKET ACCESS AND REIMBURSEMENT

18 AMYOTROPHIC LATERAL SCLEROSIS (ALS): SEVEN MAJOR MARKET ANALYSIS

- 18.1 Key Findings
- 18.2 Market Size of Amyotrophic Lateral Sclerosis (ALS) in the 7MM
- 18.3 Market Size by Current Therapies in the 7MM
- 18.4 Market Size by Emerging Therapies in the 7MM

19 7MM MARKET OUTLOOK

- 19.1 United States Market Size
 - 19.1.1 Total Market size of Amyotrophic Lateral Sclerosis
 - 19.1.2 Market Size by Current Therapies
 - 19.1.3 Market Size by Emerging Therapies
- 19.2 EU5 Market Size

19.3 Germany

19.3.1 Total Market size of Amyotrophic Lateral Sclerosis

19.3.2 Market Size by Current Therapies

19.3.3 Market Size by Emerging Therapies

19.4 France

19.4.1 Total Market size of Amyotrophic Lateral Sclerosis

19.4.2 Market Size by Current Therapies

19.4.3 Market Size by Emerging Therapies

19.5 Italy

19.5.1 Total Market size of Amyotrophic Lateral Sclerosis

19.5.2 Market Size by Current Therapies

19.5.3 Market Size by Emerging Therapies

19.6 Spain

19.6.1 Total Market size of Amyotrophic Lateral Sclerosis

19.6.2 Market Size by Current Therapies

19.6.3 Market Size by Emerging Therapies

19.7 United Kingdom

19.7.1 Total Market size of Amyotrophic Lateral Sclerosis

19.7.2 Market Size by Current Therapies

19.7.3 Market Size by Emerging Therapies

19.8 Japan Market Size

19.8.1 Total Market size of Amyotrophic Lateral Sclerosis

19.8.2 Market Size by Current Therapies

19.8.3 Market Size by Emerging Therapies

20 CASE REPORTS

21 MARKET DRIVERS

22 MARKET BARRIERS

23 SWOT ANALYSIS

24 APPENDIX

24.1 Bibliography

24.2 Report Methodology

25 DELVEINSIGHT CAPABILITIES

26 DISCLAIMER

27 ABOUT DELVEINSIGHT

List Of Tables

LIST OF TABLES

- Table 1: Summary of ALS, Market, Epidemiology and Key Events (2017–2030)
- Table 2: List of differential diagnosis and clinical overlap with ALS
- Table 3: Summary table of amyotrophic lateral sclerosis and key differentiating factors with each mimic/variant
- Table 4: Diagnostic tests for ALS
- Table 5: Revised El Escorial Criteria for ALS
- Table 6: Recognized Establishments for ALS
- Table 7: Neuroprotective and Symptomatic Treatments for ALS
- Table 8: Clinical practice and treatment guidelines for ALS in Japan, the United States, and Europe.
- Table 9: Prevalent Population of Amyotrophic Lateral Sclerosis in the 7MM (2017–2030)
- Table 10: Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in the 7MM (2017–2030)
- Table 11: Prevalence of Amyotrophic Lateral Sclerosis in the US (2017–2030)
- Table 12: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in the US (2017–2030)
- Table 13: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in the US (2017–2030)
- Table 14: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in the US (2017–2030)
- Table 15: Type-specific Distribution of Amyotrophic Lateral Sclerosis in the US (2017–2030)
- Table 16: Site of onset of Amyotrophic Lateral Sclerosis in the US (2017–2030)
- Table 17: Age-specific Distribution of Amyotrophic Lateral Sclerosis in the US (2017–2030)
- Table 18: Prevalence of Amyotrophic Lateral Sclerosis in Germany (2017–2030)
- Table 19: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in Germany (2017–2030)
- Table 20: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in Germany (2017–2030)
- Table 21: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in Germany (2017–2030)
- Table 22: Type-specific Distribution of Amyotrophic Lateral Sclerosis in Germany (2017–2030)
- Table 23: Site of onset of Amyotrophic Lateral Sclerosis in Germany (2017–2030)

Table 24: Age-specific Distribution of Amyotrophic Lateral Sclerosis in Germany (2017–2030)

Table 25: Prevalence of Amyotrophic Lateral Sclerosis in France (2017–2030)

Table 26: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in France (2017–2030)

Table 27: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in France (2017–2030)

Table 28: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in France (2017–2030)

Table 29: Type-specific Distribution of Amyotrophic Lateral Sclerosis in France (2017–2030)

Table 30: Site of onset of Amyotrophic Lateral Sclerosis in France (2017–2030)

Table 31: Age-specific Distribution of Amyotrophic Lateral Sclerosis in France (2017–2030)

Table 32: Prevalence of Amyotrophic Lateral Sclerosis in Italy (2017–2030)

Table 33: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in Italy (2017–2030)

Table 34: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in Italy (2017–2030)

Table 35: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in Italy (2017–2030)

Table 36: Type-specific Distribution of Amyotrophic Lateral Sclerosis in Italy (2017–2030)

Table 37: Site of onset of Amyotrophic Lateral Sclerosis in Italy (2017–2030)

Table 38: Age-specific Distribution of Amyotrophic Lateral Sclerosis in Italy (2017–2030)

Table 39: Prevalence of Amyotrophic Lateral Sclerosis in Spain (2017–2030)

Table 40: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in Spain (2017–2030)

Table 41: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in Spain (2017–2030)

Table 42: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in Spain (2017–2030)

Table 43: Type-specific Distribution of Amyotrophic Lateral Sclerosis in Spain (2017–2030)

Table 44: Site of onset of Amyotrophic Lateral Sclerosis in Spain (2017–2030)

Table 45: Age-specific Distribution of Amyotrophic Lateral Sclerosis in Spain (2017–2030)

Table 46: Prevalence of Amyotrophic Lateral Sclerosis in the UK (2017–2030)

Table 47: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in the UK (2017–2030)

Table 48: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in the UK

(2017–2030)

Table 49: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in the UK
(2017–2030)

Table 50: Type-specific Distribution of Amyotrophic Lateral Sclerosis in the UK
(2017–2030)

Table 51: Site of onset of Amyotrophic Lateral Sclerosis in the UK (2017–2030)

Table 52: Age-specific Distribution of Amyotrophic Lateral Sclerosis in the UK
(2017–2030)

Table 53: Prevalence of Amyotrophic Lateral Sclerosis in Japan (2017–2030)

Table 54: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in Japan
(2017–2030)

Table 55: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in Japan
(2017–2030)

Table 56: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in Japan
(2017–2030)

Table 57: Type-specific Distribution of Amyotrophic Lateral Sclerosis in Japan
(2017–2030)

Table 58: Site of onset of Amyotrophic Lateral Sclerosis in Japan (2017–2030)

Table 59: Age-specific Distribution of Amyotrophic Lateral Sclerosis in Japan
(2017–2030)

Table 60: Comparison of marketed drugs

Table 61: Patent Expiration

Table 62: Patent Expiration

Table 63: Patent Expiration

Table 64: Patent Expiration

Table 65: Comparison of Emerging Drugs

Table 66: Arimoclomol, Clinical Trial Description, 2020

Table 67: Tofersen, Clinical Trial Description, 2020

Table 68: Levosimendan; Clinical Trial Description, 2020

Table 69: NurOwn, Clinical Trial Description, 2020

Table 70: Masitinib; Clinical Trial Description, 2020

Table 71: Ravulizumab; Clinical Trial Description, 2020

Table 72: Tirasemtiv, Clinical Trial Description, 2020

Table 73: Verdiperstat, Clinical Trial Description, 2020

Table 74: MN-166 (Ibudilast); Clinical Trial Description, 2020

Table 75: AMX0035; Clinical Trial Description, 2020

Table 76: Zilucoplan; Clinical Trial Description, 2020

Table 77: CNM-Au8, Clinical Trial Description, 2020

Table 78: ALZT-OP1a (cromolyn); Clinical Trial Description, 2020

Table 79: Reldesemtiv, Clinical Trial Description, 2020
Table 80: RNS60, Clinical Trial Description, 2020
Table 81: ANX005, Clinical Trial Description, 2020
Table 82: PU-AD, Clinical Trial Description, 2020
Table 83: Ezogabine, Clinical Trial Description, 2020
Table 84: Pegcetacoplan, Clinical Trial Description, 2020
Table 85: AT-1501; Clinical Trial Description, 2020
Table 86: Ranolazine; Clinical Trial Description, 2020
Table 87: ILB; Clinical Trial Description, 2020
Table 88: BLZ945, Clinical Trial Description, 2020
Table 89: EPI-589, Clinical Trial Description, 2020
Table 90: BIIB078, Clinical Trial Description, 2020
Table 91: BIIB105, Clinical Trial Description, 2020
Table 92: Seven Major Market Size of ALS in USD Million (2017–2030)
Table 93: Market size of ALS by current therapies in the 7MM, in USD Million (2017–2030)
Table 94: Market size of ALS by emerging therapies in the 7MM, in USD Million (2017–2030)
Table 95: Launch dates of potential emerging drugs
Table 96: Total Market Size of ALS in the United States, in USD Million (2017–2030)
Table 97: Market size of ALS by current therapies in the United States, in USD Million (2017–2030)
Table 98: Market size of ALS by emerging therapies in the United States, in USD Million (2017–2030)
Table 99: Total Market Size of ALS in Germany, in USD Million (2017–2030)
Table 100: Market size of ALS by current therapies in Germany, in USD Million (2017–2030)
Table 101: Market size of ALS by emerging therapies in Germany, in USD Million (2017–2030)
Table 102: Total Market Size of ALS in France, in USD Million (2017–2030)
Table 103: Market size of ALS by current therapies France, in USD Million (2017–2030)
Table 104: Market size of ALS by emerging therapies France, in USD Million (2017–2030)
Table 105: Total Market Size of ALS in Italy, in USD Million (2017–2030)
Table 106: Market size of ALS by current therapies in Italy, in USD Million (2017–2030)
Table 107: Market size of ALS by emerging therapies in Italy, in USD Million (2017–2030)
Table 108: Total Market Size of ALS in Spain, in USD Million (2017–2030)
Table 109: Market size of ALS by current therapies in Spain, in USD Million

(2017–2030)

Table 110: Market size of ALS by emerging therapies in Spain, in USD Million

(2017–2030)

Table 111: Total Market Size of ALS in the United Kingdom, in USD Million (2017–2030)

Table 112: Market size of ALS by current therapies in the United Kingdom, in USD Million (2017–2030)

Table 113: Market size of ALS by emerging therapies in the United Kingdom, in USD Million (2017–2030)

Table 114: Total Market Size of ALS in Japan, in USD Million (2017–2030)

Table 115: Market size of ALS by current therapies in Japan, in USD Million (2017–2030)

Table 116: Market size of ALS by emerging therapies in Japan, in USD Million (2017–2030)

List Of Figures

LIST OF FIGURES

Figure 1: Phenotypic presentations of ALS.

Figure 2: Clustering of ALS genes in pathogenic pathways.

Figure 3: Flowchart for the management of respiratory dysfunction in ALS/ motor neuron disease (MND)

Figure 4: Prevalent Population of Amyotrophic Lateral Sclerosis in the 7MM (2017–2030)

Figure 5: Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis in the 7MM (2017–2030)

Figure 6: Prevalence of Amyotrophic Lateral Sclerosis in the US (2017–2030)

Figure 7: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in the US (2017–2030)

Figure 8: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in the US (2017–2030)

Figure 9: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in the US (2017–2030)

Figure 10: Type-specific Distribution of Amyotrophic Lateral Sclerosis in the US (2017–2030)

Figure 11: Site of onset of Amyotrophic Lateral Sclerosis in the US (2017–2030)

Figure 12: Age-specific Distribution of Amyotrophic Lateral Sclerosis in the US (2017–2030)

Figure 13: Prevalence of Amyotrophic Lateral Sclerosis in Germany (2017–2030)

Figure 14: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in Germany (2017–2030)

Figure 15: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in Germany (2017–2030)

Figure 16: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in Germany (2017–2030)

Figure 17: Type-specific Distribution of Amyotrophic Lateral Sclerosis in Germany (2017–2030)

Figure 18: Site of onset of Amyotrophic Lateral Sclerosis in Germany (2017–2030)

Figure 19: Age-specific Distribution of Amyotrophic Lateral Sclerosis in Germany (2017–2030)

Figure 20: Prevalence of Amyotrophic Lateral Sclerosis in France (2017–2030)

Figure 21: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in France (2017–2030)

Figure 22: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in France (2017–2030)

Figure 23: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in France (2017–2030)

Figure 24: Type-specific Distribution of Amyotrophic Lateral Sclerosis in France (2017–2030)

Figure 25: Site of onset of Amyotrophic Lateral Sclerosis in France (2017–2030)

Figure 26: Age-specific Distribution of Amyotrophic Lateral Sclerosis in France (2017–2030)

Figure 27: Prevalence of Amyotrophic Lateral Sclerosis in Italy (2017–2030)

Figure 28: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in Italy (2017–2030)

Figure 29: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in Italy (2017–2030)

Figure 30: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in Italy (2017–2030)

Figure 31: Type-specific Distribution of Amyotrophic Lateral Sclerosis in Italy (2017–2030)

Figure 32: Site of onset of Amyotrophic Lateral Sclerosis in Italy (2017–2030)

Figure 33: Age-specific Distribution of Amyotrophic Lateral Sclerosis in Italy (2017–2030)

Figure 34: Prevalence of Amyotrophic Lateral Sclerosis in Spain (2017–2030)

Figure 35: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in Spain (2017–2030)

Figure 36: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in Spain (2017–2030)

Figure 37: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in Spain (2017–2030)

Figure 38: Type-specific Distribution of Amyotrophic Lateral Sclerosis in Spain (2017–2030)

Figure 39: Site of onset of Amyotrophic Lateral Sclerosis in Spain (2017–2030)

Figure 40: Age-specific Distribution of Amyotrophic Lateral Sclerosis in Spain (2017–2030)

Figure 41: Prevalence of Amyotrophic Lateral Sclerosis in the UK (2017–2030)

Figure 42: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in the UK (2017–2030)

Figure 43: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in the UK (2017–2030)

Figure 44: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in the UK (2017–2030)

Figure 45: Type-specific Distribution of Amyotrophic Lateral Sclerosis in the UK (2017–2030)

Figure 46: Site of onset of Amyotrophic Lateral Sclerosis in the UK (2017–2030)

Figure 47: Age-specific Distribution of Amyotrophic Lateral Sclerosis in the UK (2017–2030)

Figure 48: Prevalence of Amyotrophic Lateral Sclerosis in Japan (2017–2030)

Figure 49: Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in Japan (2017–2030)

Figure 50: Gender-specific Distribution of Amyotrophic Lateral Sclerosis in Japan (2017–2030)

Figure 51: Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in Japan (2017–2030)

Figure 52: Type-specific Distribution of Amyotrophic Lateral Sclerosis in Japan (2017–2030)

Figure 53: Site of onset of Amyotrophic Lateral Sclerosis in Japan (2017–2030)

Figure 54: Age-specific Distribution of Amyotrophic Lateral Sclerosis in Japan (2017–2030)

Figure 55: Unmet Needs of ALS

Figure 56: Seven Major Market Size of ALS in USD Million (2017–2030)

Figure 57: Market size of ALS by current therapies in the 7MM, in USD Million (2017–2030)

Figure 58: Market size of ALS by emerging therapies in the 7MM, in USD Million (2017–2030)

Figure 59: Total Market Size of ALS in the United States, USD Millions (2017–2030)

Figure 60: Market size of ALS by current therapies in the United States, in USD Million (2017–2030)

Figure 61: Market size of ALS by emerging therapies in the United States, in USD Million (2017–2030)

Figure 62: Total Market Size of ALS in Germany, USD Millions (2017–2030)

Figure 63: Market size of ALS by current therapies in Germany, in USD Million (2017–2030)

Figure 64: Market size of ALS by emerging therapies in Germany, in USD Million (2017–2030)

Figure 65: Total Market Size of ALS in France, USD Millions (2017–2030)

Figure 66: Market size of ALS by current therapies in France, in USD Million (2017–2030)

Figure 67: Market size of ALS by emerging therapies in France, in USD Million (2017–2030)

Figure 68: Total Market Size of ALS in Italy, USD Millions (2017–2030)

Figure 69: Market size of ALS by current therapies in Italy, in USD Million (2017–2030)

Figure 70: Market size of ALS by emerging therapies in Italy, in USD Million (2017–2030)

Figure 71: Total Market Size of ALS in Spain, USD Millions (2017–2030)

Figure 72: Market size of ALS by current therapies in Spain, in USD Million (2017–2030)

Figure 73: Market size of ALS by emerging therapies in Spain, in USD Million (2017–2030)

Figure 74: Total Market Size of ALS in the United Kingdom, USD Millions (2017–2030)

Figure 75: Market size of ALS by current therapies in the United Kingdom, in USD Million (2017–2030)

Figure 76: Market size of ALS by emerging therapies in the United Kingdom, in USD Million (2017–2030)

Figure 77: Total Market Size of ALS in Japan, USD Millions (2017–2030)

Figure 78: Market size of ALS by cu

I would like to order

Product name: Amyotrophic Lateral Sclerosis Market Insight, Epidemiology and Market Forecast -2030

Product link: <https://marketpublishers.com/r/A021C3B2A874EN.html>

Price: US\$ 6,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A021C3B2A874EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970